ACL Graft Market

The global ACL graft market is valued at an estimated USD 0.12 billion in 2024 and is projected to reach USD 0.18 billion by 2029, at a CAGR of 7.2% during the forecast period. Growth in the ACL graft market is primarily driven by the increasing awareness about ACL injuries along with advancements in the surgical techniques and improved graft material. While expansion of healthcare facilities is an opportunity for the ACL graft market.

The global ACL graft market is consolidated in nature and has players mostly operating in the regional markets. The top three players operating in this market are AlloSource (US), RTI Surgical (US), and MTF Biologics (US). Players in this market are focusing on adopting organic growth strategies such as product launch and approval to increase their ACL graft offerings, cater to customer needs, increase their profitability, and expand their presence in the global ACL graft market.

To know about the assumptions considered for the study download the pdf brochure

ALLOSOURCE (US)

In 2023, AlloSource held a commanding market dominance in the ACL graft market. AlloSource is a company that develops, produces, and distributes orthopedic, skin, and spinal grafts as well as biologic allografts. The company has one of the largest tissue networks in the US that offers more than 200 types of bone, skin and soft-tissue allografts that are used in a broad range of life-saving and life-enhancing medical procedures. The company has focused on extending its product portfolio in the ACL graft market through organic growth strategies. The company has recently introduced a new category of products in its line of allografts. Such developments have enabled the company to hold a strong position in the market.

RTI SURGICAL (US)

With a significant market share in 2023, RTI Surgical (US) established itself as a second major participant in the ACL graft market. RTI Surgical offers a broad range of allografts in the ACL market. The company has a distinctive product portfolio that are used across a wide range of applications such as Sports Medicine, Plastic & Reconstructive Surgery. Other than being a manufacturer of the implants needed for surgeries, the company also is an OEM and provides allograft soft tissue, xenograft soft tissue, allograft bone, structural allografts, and allograft demineralized bone grafts. The company has four state-of-the-art manufacturing facilities in Alachua, Florida (US); Marquette, Michigan (US); Neunkirchen (Germany); and Greenville, North Carolina (US).

MTF BIOLOGICS (US)

MTF Biologics is among the leading players offering products used for wound care, orthopedics, and reconstructive surgeries. The company provides grafts used for ACL reconstruction. MTF Biologics is among the prominent providers of allografts in the US market. The company has the largest selection of allograft tissue in the nation, with is more than 1,000 allografts. MTF Biologics has a well organized supply chain, which includes 48 Academic Members and it recovers tissue through an a diverse network of recovery organizations, half of which are US's federally designated organ procurement organizations and tissue banks. These factors make MTF Biologics as a reliable option for end users looking to procure allografts.

Related Reports:

ACL Graft Market by Type of ACL Surgery (Reconstruction, Revision), Age (Above & Below 19 years), Gender (Male, Female), Injury (Sports Injuries (Basketball, Football), Non-sports Injuries (Road Accidents, Falls)), End User - Global Forecast to 2029

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]